LC
Therapeutic Areas
Jaguar Health Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Mytesi (crofelemer) | Symptomatic relief of non-infectious diarrhea in adult HIV/AIDS patients on antiretroviral therapy (ART) | Approved/Commercial |
| Crofelemer | Cancer Therapy-Related Diarrhea (CTD) - Prophylaxis for targeted therapy-induced diarrhea | Phase 3 |
| Crofelemer (Animal Health) | Chemotherapy-Induced Diarrhea in dogs | Preclinical |
Leadership Team at Jaguar Health
CR
Carol R. Lizak
Chief Financial Officer
PR
Pravin R. Chaturvedi, Ph.D.
Chief Scientific Officer, Chairman of Scientific Advisory Board
JS
Jonathan S. Wolin
General Counsel and Corporate Secretary
JR
James R. Brown
Vice President of Commercial Operations
SB
Steven B. King, Ph.D.
Executive Vice President of Sustainable Supply, Ethnobotanical Research, and Intellectual Property
CD
Carolyn D. Beaver
Vice President, Controller
PH
Peter H. Mordy
Chairman of the Board of Directors
SR
S. Russell McGlothlin
Board Member
AD
Ann D. Rhoads
Board Member
AH
Andrew H. Ko, M.D.
Scientific Advisory Board Member (Oncology)